ITM and Scil Proteins Announce Partnership
News Mar 25, 2016

ITM Isotopen Technologien München AG and Scil Proteins have announced they have entered into a partnership covering the field of targeted radio conjugates. Under the terms of the agreement the partners plan to cover a number of programs for the discovery and development of novel targeted radio conjugates for imaging and therapy purposes, in a variety of indications.
Scil Proteins will be responsible for the discovery and design of the radio conjugates based on its proprietary Affilin® platform, while ITM will use its radioisotope technology and be responsible for later-stage development and commercialization of the resulting products. The first program has
commenced in the area of targeted cancer treatment.
Henning Afflerbach, CEO of Scil Proteins commented: “ITM has outstanding capabilities and deep expertise in targeted radionuclide imaging and radionuclide therapy and this collaboration reinforces our leadership in the generation of targeted carriers as homogenous products specifically tailored to imaging and therapy applications.”
“We have been impressed by the potential of Scil’s platform to deliver compounds with precisely engineered carriers”, added Steffen Schuster, CEO of ITM. “This enables us to select the compounds half-lives, short-term for imaging applications and longer-term for therapeutic applications – a perfect fit to our precision oncology strategy.”
Affilin® -based biomolecules are derived from human scaffold proteins and have high stability, affinity and specificity making them ideal for a range of applications, including those where antibodies have limitations, thus broadening the potential of biotherapeutics.
RELATED ARTICLES
New Microscope Captures Detailed 3-D Movies of Cells Deep Within Living Systems
NewsMerging lattice light sheet microscopy with adaptive optics reveals the most detailed picture yet of subcellular dynamics in multicellular organisms.
READ MOREReversing an Unstoppable Cancer Cascade with Proteomics
NewsMutations in genes that produce RAS proteins turn a normally benign process, essential for cellular growth, into a cancer stimulant that is currently undruggable. Now, cutting-edge protein analysis may help treat cancers caused by these mutations.
READ MOREA New, Streamlined Approach to Diagnosing and Treating Bowel Cancer
NewsResearchers at the South Australian Health and Medical Research Institute (SAHMRI) and the University of Adelaide have discovered a faster, more cost-effective way to determine which DNA mutations cause human bowel cancer.
READ MOREComments | 0 ADD COMMENT
To personalize the content you see on Technology Networks homepage, Log In or Subscribe for Free
LOGIN SUBSCRIBE FOR FREEWorld Congress on Advanced Biomaterials and Tissue Engineering
Jun 20 - Jun 21, 2018
29th International Conference on Public Mental Health and Neuroscience
Jul 16 - Jul 18, 2018
Login
You must be logged in to post a comment.